시장보고서

상품코드

1786787

세계의 비소세포 폐암(NSCLC) 시장 : 규모, 점유율, 동향, 산업 분석 보고서 - 유형별, 치료별, 유통 채널별, 지역별 시장 예측(2025-2034년)

Non-Small Cell Lung Cancer Market Size, Share, Trends, & Industry Analysis Report By Type, By Treatment (Chemotherapy, Targeted Therapy, Immunotherapy, and Others), By Distribution Channel, and By Region - Market Forecast, 2025-2034

발행일: 2025년 07월 | 리서치사:

Polaris Market Research | 페이지 정보: 영문 129 Pages | 배송안내 : 1-2일 (영업일 기준)

샘플 요청 목록에 추가

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

Polaris Market Research의 최신 조사에 따르면 비소세포 폐암(NSCLC) 시장 규모는 2034년까지 1,298억 8,000만 달러에 이를 전망입니다. 이 보고서는 현재 시장 역학을 상세하게 파악하고 미래 시장 성장에 대한 분석을 제공합니다.

비소세포 폐암(NSCLC)은 세계 폐암 증례의 대부분을 차지하고 정밀 종양학의 진보를 견인하고 있습니다. 바이오마커 검사, 표적요법, 면역요법의 이용이 증가하고 치료방법이 재구성되고 있는 한편, 리퀴드 바이옵시나 변이 특이적 약제의 혁신이 조기 진단 및 결과의 개선을 가능하게 하고 있습니다.

시장 성장의 주요 원동력은 NSCLC의 세계 이환율 증가, 표적 요법 및 면역 요법 채택 증가, 개인화 치료 계획을 지원하는 동반진단약의 가용성 확대입니다.

비소세포 폐암(NSCLC) 시장 보고서 하이라이트

유형별로는 높은 이환율 및 표적 치료 옵션에 대한 강한 반응성으로 2024년 시장 점유율은 선암 부문이 우위를 차지했습니다.

치료별로, EGFR, ALK, KRAS 억제제의 광범위한 임상 사용을 지원하고, 표적 치료 부문이 2024년 시장을 독점했습니다.

유통 채널별로는 선진적인 암 치료제에 대한 집중적인 접근과 임상 모니터링으로 병원 약국 부문이 2024년 시장을 독점했습니다.

2024년 세계 비소세포 폐암(NSCLC) 시장에서는 분자진단법의 조기 도입 및 신규 치료에 대한 규제 당국의 지원으로 북미가 대부분의 점유율을 차지했습니다.

아시아태평양은 암 이환율 증가, 의료 접근 확대, 종양학 연구 투자 증가로 예측 기간 동안 가장 빠른 CAGR로 성장할 것으로 예측됩니다.

세계의 주요 시장 기업 : Roche Holding AG, AstraZeneca PLC, Merck & Co. 등

시장 현황
비소세포 폐암(NSCLC) 시장 역학
- 성장 촉진요인 및 기회
  - 세계에서 급증하는 비소세포 폐암(NSCLC) 증례
  - 액체 생검 및 멀티플렉스 검사 플랫폼의 임상 도입 증가
- 성장 억제요인 및 과제
  - 고도의 진단 툴에 수반하는 고비용
PESTEL 분석
비소세포 폐암(NSCLC) 시장 동향
밸류체인 분석

제5장 세계의 비소세포 폐암(NSCLC) 시장 : 유형별

주요 조사 결과
서문
편평상피암
대세포암
선암암
기타

제6장 세계의 비소세포 폐암(NSCLC) 시장 : 치료별

주요 조사 결과
서문
화학요법
표적요법
면역요법
기타

제7장 세계의 비소세포 폐암(NSCLC) 시장 : 유통 채널별

주요 조사 결과
서문
병원 약국
약국 및 소매 약국
온라인 약국

제8장 세계의 비소세포 폐암(NSCLC) 시장 : 지역별

주요 조사 결과
서문
- 비소세포 폐암(NSCLC) 시장 평가 : 지역별(2020-2034년)
북미
- 북미 : 유형별(2020-2034년)
- 북미 : 치료별(2020-2034년)
- 북미 : 유통 채널별(2020-2034년)
- 미국
- 캐나다
유럽
- 유럽 : 유형별(2020-2034년)
- 유럽 : 치료별(2020-2034년)
- 유럽 : 유통 채널별(2020-2034년)
- 영국
- 프랑스
- 독일
- 이탈리아
- 스페인
- 네덜란드
- 러시아
- 기타 유럽
아시아태평양
- 아시아태평양 : 유형별(2020-2034년)
- 아시아태평양 : 치료별(2020-2034년)
- 아시아태평양 : 유통 채널별(2020-2034년)
- 중국
- 인도
- 말레이시아
- 일본
- 인도네시아
- 한국
- 호주
- 기타 아시아태평양
중동 및 아프리카
- 중동 및 아프리카 : 유형별(2020-2034년)
- 중동 및 아프리카 : 치료별(2020-2034년)
- 중동 및 아프리카 : 유통 채널별(2020-2034년)
- 사우디아라비아
- 아랍에미리트(UAE)
- 이스라엘
- 남아프리카
- 기타 중동 및 아프리카
라틴아메리카
- 라틴아메리카 : 유형별(2020-2034년)
- 라틴아메리카 : 치료별(2020-2034년)
- 라틴아메리카 : 유통 채널별(2020-2034년)
- 멕시코
- 브라질
- 아르헨티나
- 기타 라틴아메리카

제9장 경쟁 구도

확대 및 인수 분석
- 확대
- 인수
제휴, 협업, 합의 및 공개

제10장 기업 프로파일

Amgen Inc.
AstraZeneca PLC
Beigene Ltd.
Bristol-Myers Squibb Company
Eli Lilly And Company
Exelixis Inc.
Johnson & Johnson
Merck & Co., Inc.
Mirati Therapeutics Inc.
Novartis AG
Pfizer Inc.
Roche Holding AG

AJY 25.08.18

The non-small cell lung cancer market size is expected to reach USD 129.88 Billion by 2034, according to a new study by Polaris Market Research. The report "Non-Small Cell Lung Cancer Market Share, Size, Trends, Industry Analysis Report: By Type, By Treatment (Chemotherapy, Targeted Therapy, Immunotherapy, and Others), By Distribution Channel, and By Region; Market Forecast, 2025-2034" gives a detailed insight into current market dynamics and provides analysis on future market growth.

Non-small cell lung cancer (NSCLC) represents the majority of global lung cancer cases and is driving advances in precision oncology. Increasing use of biomarker testing, targeted therapies, and immunotherapies is reshaping treatment approaches, while innovations in liquid biopsy and mutation-specific drugs are enabling earlier diagnosis and better outcomes.

Market growth is primarily driven by the rising global incidence of NSCLC, increasing adoption of targeted and immune-based therapies and the growing availability of companion diagnostics that support personalized treatment plans.

Non-Small Cell Lung Cancer Market Report Highlights

Based on type, the adenocarcinoma segment dominated the market share in 2024, driven by its high prevalence and strong response to targeted therapy options.

In terms of treatment, the targeted therapy segment dominated the market in 2024, supported by the broad clinical use of EGFR, ALK, and KRAS inhibitors.

Based on distribution channel, the hospital pharmacy segment dominated the market in 2024, due to centralized access to advanced oncology drugs and clinical oversight.

North America accounted for the majority share in the global non-small cell lung cancer market in 2024, driven by early adoption of molecular diagnostics and regulatory support for novel therapies.

Asia Pacific is projected to grow at the fastest CAGR during the forecast period, owing to rising cancer incidence, expanding healthcare access, and growing investment in oncology research.

A few global key market players include Roche Holding AG, AstraZeneca PLC, Merck & Co., Inc., Bristol-Myers Squibb Company, Pfizer Inc., Eli Lilly And Company, Novartis AG, Johnson & Johnson, Amgen Inc., Beigene Ltd., Exelixis Inc., and Mirati Therapeutics Inc.

Polaris Market Research has segmented the market report on the basis of type, treatment, distribution channel, and region:

By Type Outlook (Revenue, USD Billion, 2020-2034)

Squamous Cell Carcinoma

Large Cell Carcinoma

Adenocarcinoma

Other Type

By Treatment Outlook (Revenue, USD Billion, 2020-2034)

Chemotherapy

Targeted Therapy

Immunotherapy

Others

By Distribution Channel Outlook (Revenue, USD Billion, 2020-2034)

Hospital Pharmacy

Drug Store and Retail Pharmacy

Online Pharmacy

By Regional Outlook (Revenue, USD Billion, 2020-2034)

North America

Canada

Europe

Germany

France

Italy

Spain

Netherlands

Russia

Rest of Europe

Asia Pacific

China

Japan

India

Malaysia

South Korea

Indonesia

Australia

Vietnam

Rest of Asia Pacific

Middle East & Africa

Saudi Arabia

UAE

Israel

South Africa

Rest of Middle East & Africa

Latin America

Mexico

Brazil

Argentina

Rest of Latin America

1. Introduction

1.1. Report Description
- 1.1.1. Objectives of the Study
- 1.1.2. Market Scope
- 1.1.3. Assumptions
1.2. Stakeholders

2. Executive Summary

2.1. Market Highlights

3. Research Methodology

3.1. Overview
- 3.1.1. Data Mining
3.2. Data Sources
- 3.2.1. Primary Sources
- 3.2.2. Secondary Sources

4. Global Non-Small Cell Lung Cancer Market Insights

4.1. Non-Small Cell Lung Cancer Market - Market Snapshot
4.2. Non-Small Cell Lung Cancer Market Dynamics
- 4.2.1. Drivers and Opportunities
  - 4.2.1.1. Rapidly Rising Cases of NSCLC Globally
  - 4.2.1.2. Increasing Clinical Adoption of Liquid Biopsies and Multiplexed Testing Platforms
- 4.2.2. Restraints and Challenges
  - 4.2.2.1. High Costs Associated with Advanced Diagnostic Tools
4.3. Porter's Five Forces Analysis
- 4.3.1. Bargaining Power of Suppliers (Moderate)
- 4.3.2. Threats of New Entrants: (Low)
- 4.3.3. Bargaining Power of Buyers (Moderate)
- 4.3.4. Threat of Substitute (Moderate)
- 4.3.5. Rivalry among existing firms (High)
4.4. PESTEL Analysis
4.5. Non-Small Cell Lung Cancer Market Trends
4.6. Value Chain Analysis

5. Global Non-Small Cell Lung Cancer Market, by Type

5.1. Key Findings
5.2. Introduction
- 5.2.1. Global Non-Small Cell Lung Cancer Market, by Type, 2020-2034 (USD Billion)
5.3. Squamous Cell Carcinoma
- 5.3.1. Global Non-Small Cell Lung Cancer Market, by Squamous Cell Carcinoma, by Region, 2020-2034 (USD Billion)
5.4. Large Cell Carcinoma
- 5.4.1. Global Non-Small Cell Lung Cancer Market, by Large Cell Carcinoma, by Region, 2020-2034 (USD Billion)
5.5. Adenocarcinoma
- 5.5.1. Global Non-Small Cell Lung Cancer Market, by Adenocarcinoma, by Region, 2020-2034 (USD Billion)
5.6. Other Type
- 5.6.1. Global Non-Small Cell Lung Cancer Market, by Other Type, by Region, 2020-2034 (USD Billion)

6. Global Non-Small Cell Lung Cancer Market, by Treatment

6.1. Key Findings
6.2. Introduction
- 6.2.1. Global Non-Small Cell Lung Cancer Market, by Treatment, 2020-2034 (USD Billion)
6.3. Chemotherapy
- 6.3.1. Global Non-Small Cell Lung Cancer Market, by Chemotherapy, by Region, 2020-2034 (USD Billion)
6.4. Targeted Therapy
- 6.4.1. Global Non-Small Cell Lung Cancer Market, by Targeted Therapy, by Region, 2020-2034 (USD Billion)
6.5. Immunotherapy
- 6.5.1. Global Non-Small Cell Lung Cancer Market, by Immunotherapy, by Region, 2020-2034 (USD Billion)
6.6. Others
- 6.6.1. Global Non-Small Cell Lung Cancer Market, by Others, by Region, 2020-2034 (USD Billion)

7. Global Non-Small Cell Lung Cancer Market, by Distribution Channel

7.1. Key Findings
7.2. Introduction
- 7.2.1. Global Non-Small Cell Lung Cancer Market, by Distribution Channel, 2020-2034 (USD Billion)
7.3. Hospital Pharmacy
- 7.3.1. Global Non-Small Cell Lung Cancer Market, by Hospital Pharmacy, by Region, 2020-2034 (USD Billion)
7.4. Drug Store and Retail Pharmacy
- 7.4.1. Global Non-Small Cell Lung Cancer Market, by Drug Store and Retail Pharmacy, by Region, 2020-2034 (USD Billion)
7.5. Online Pharmacy
- 7.5.1. Global Non-Small Cell Lung Cancer Market, by Online Pharmacy, by Region, 2020-2034 (USD Billion)

8. Global Non-Small Cell Lung Cancer Market, by Geography

8.1. Key Findings
8.2. Introduction
- 8.2.1. Non-Small Cell Lung Cancer Market Assessment, By Geography, 2020-2034 (USD Billion)
8.3. Non-Small Cell Lung Cancer Market - North America
- 8.3.1. North America: Non-Small Cell Lung Cancer Market, by Type, 2020-2034 (USD Billion)
- 8.3.2. North America: Non-Small Cell Lung Cancer Market, by Treatment, 2020-2034 (USD Billion)
- 8.3.3. North America: Non-Small Cell Lung Cancer Market, by Distribution Channel, 2020-2034 (USD Billion)
- 8.3.4. Non-Small Cell Lung Cancer Market - U.S.
  - 8.3.4.1. U.S.: Non-Small Cell Lung Cancer Market, by Type, 2020-2034 (USD Billion)
  - 8.3.4.2. U.S.: Non-Small Cell Lung Cancer Market, by Treatment, 2020-2034 (USD Billion)
  - 8.3.4.3. U.S.: Non-Small Cell Lung Cancer Market, by Distribution Channel, 2020-2034 (USD Billion)
- 8.3.5. Non-Small Cell Lung Cancer Market - Canada
  - 8.3.5.1. Canada: Non-Small Cell Lung Cancer Market, by Type, 2020-2034 (USD Billion)
  - 8.3.5.2. Canada: Non-Small Cell Lung Cancer Market, by Treatment, 2020-2034 (USD Billion)
  - 8.3.5.3. Canada: Non-Small Cell Lung Cancer Market, by Distribution Channel, 2020-2034 (USD Billion)
8.4. Non-Small Cell Lung Cancer Market - Europe
- 8.4.1. Europe: Non-Small Cell Lung Cancer Market, by Type, 2020-2034 (USD Billion)
- 8.4.2. Europe: Non-Small Cell Lung Cancer Market, by Treatment, 2020-2034 (USD Billion)
- 8.4.3. Europe: Non-Small Cell Lung Cancer Market, by Distribution Channel, 2020-2034 (USD Billion)
- 8.4.4. Non-Small Cell Lung Cancer Market - UK
  - 8.4.4.1. UK: Non-Small Cell Lung Cancer Market, by Type, 2020-2034 (USD Billion)
  - 8.4.4.2. UK: Non-Small Cell Lung Cancer Market, by Treatment, 2020-2034 (USD Billion)
  - 8.4.4.3. UK: Non-Small Cell Lung Cancer Market, by Distribution Channel, 2020-2034 (USD Billion)
- 8.4.5. Non-Small Cell Lung Cancer Market - France
  - 8.4.5.1. France: Non-Small Cell Lung Cancer Market, by Type, 2020-2034 (USD Billion)
  - 8.4.5.2. France: Non-Small Cell Lung Cancer Market, by Treatment, 2020-2034 (USD Billion)
  - 8.4.5.3. France: Non-Small Cell Lung Cancer Market, by Distribution Channel, 2020-2034 (USD Billion)
- 8.4.6. Non-Small Cell Lung Cancer Market - Germany
  - 8.4.6.1. Germany: Non-Small Cell Lung Cancer Market, by Type, 2020-2034 (USD Billion)
  - 8.4.6.2. Germany: Non-Small Cell Lung Cancer Market, by Treatment, 2020-2034 (USD Billion)
  - 8.4.6.3. Germany: Non-Small Cell Lung Cancer Market, by Distribution Channel, 2020-2034 (USD Billion)
- 8.4.7. Non-Small Cell Lung Cancer Market - Italy
  - 8.4.7.1. Italy: Non-Small Cell Lung Cancer Market, by Type, 2020-2034 (USD Billion)
  - 8.4.7.2. Italy: Non-Small Cell Lung Cancer Market, by Treatment, 2020-2034 (USD Billion)
  - 8.4.7.3. Italy: Non-Small Cell Lung Cancer Market, by Distribution Channel, 2020-2034 (USD Billion)
- 8.4.8. Non-Small Cell Lung Cancer Market - Spain
  - 8.4.8.1. Spain: Non-Small Cell Lung Cancer Market, by Type, 2020-2034 (USD Billion)
  - 8.4.8.2. Spain: Non-Small Cell Lung Cancer Market, by Treatment, 2020-2034 (USD Billion)
  - 8.4.8.3. Spain: Non-Small Cell Lung Cancer Market, by Distribution Channel, 2020-2034 (USD Billion)
- 8.4.9. Non-Small Cell Lung Cancer Market - Netherlands
  - 8.4.9.1. Netherlands: Non-Small Cell Lung Cancer Market, by Type, 2020-2034 (USD Billion)
  - 8.4.9.2. Netherlands: Non-Small Cell Lung Cancer Market, by Treatment, 2020-2034 (USD Billion)
  - 8.4.9.3. Netherlands: Non-Small Cell Lung Cancer Market, by Distribution Channel, 2020-2034 (USD Billion)
- 8.4.10. Non-Small Cell Lung Cancer Market - Russia
  - 8.4.10.1. Russia: Non-Small Cell Lung Cancer Market, by Type, 2020-2034 (USD Billion)
  - 8.4.10.2. Russia: Non-Small Cell Lung Cancer Market, by Treatment, 2020-2034 (USD Billion)
  - 8.4.10.3. Russia: Non-Small Cell Lung Cancer Market, by Distribution Channel, 2020-2034 (USD Billion)
- 8.4.11. Non-Small Cell Lung Cancer Market - Rest of Europe
  - 8.4.11.1. Rest of Europe: Non-Small Cell Lung Cancer Market, by Type, 2020-2034 (USD Billion)
  - 8.4.11.2. Rest of Europe: Non-Small Cell Lung Cancer Market, by Treatment, 2020-2034 (USD Billion)
  - 8.4.11.3. Rest of Europe: Non-Small Cell Lung Cancer Market, by Distribution Channel, 2020-2034 (USD Billion)
8.5. Non-Small Cell Lung Cancer Market - Asia Pacific
- 8.5.1. Asia Pacific: Non-Small Cell Lung Cancer Market, by Type, 2020-2034 (USD Billion)
- 8.5.2. Asia Pacific: Non-Small Cell Lung Cancer Market, by Treatment, 2020-2034 (USD Billion)
- 8.5.3. Asia Pacific: Non-Small Cell Lung Cancer Market, by Distribution Channel, 2020-2034 (USD Billion)
- 8.5.4. Non-Small Cell Lung Cancer Market - China
  - 8.5.4.1. China: Non-Small Cell Lung Cancer Market, by Type, 2020-2034 (USD Billion)
  - 8.5.4.2. China: Non-Small Cell Lung Cancer Market, by Treatment, 2020-2034 (USD Billion)
  - 8.5.4.3. China: Non-Small Cell Lung Cancer Market, by Distribution Channel, 2020-2034 (USD Billion)
- 8.5.5. Non-Small Cell Lung Cancer Market - India
  - 8.5.5.1. India: Non-Small Cell Lung Cancer Market, by Type, 2020-2034 (USD Billion)
  - 8.5.5.2. India: Non-Small Cell Lung Cancer Market, by Treatment, 2020-2034 (USD Billion)
  - 8.5.5.3. India: Non-Small Cell Lung Cancer Market, by Distribution Channel, 2020-2034 (USD Billion)
- 8.5.6. Non-Small Cell Lung Cancer Market - Malaysia
  - 8.5.6.1. Malaysia: Non-Small Cell Lung Cancer Market, by Type, 2020-2034 (USD Billion)
  - 8.5.6.2. Malaysia: Non-Small Cell Lung Cancer Market, by Treatment, 2020-2034 (USD Billion)
  - 8.5.6.3. Malaysia: Non-Small Cell Lung Cancer Market, by Distribution Channel, 2020-2034 (USD Billion)
- 8.5.7. Non-Small Cell Lung Cancer Market - Japan
  - 8.5.7.1. Japan: Non-Small Cell Lung Cancer Market, by Type, 2020-2034 (USD Billion)
  - 8.5.7.2. Japan: Non-Small Cell Lung Cancer Market, by Treatment, 2020-2034 (USD Billion)
  - 8.5.7.3. Japan: Non-Small Cell Lung Cancer Market, by Distribution Channel, 2020-2034 (USD Billion)
- 8.5.8. Non-Small Cell Lung Cancer Market - Indonesia
  - 8.5.8.1. Indonesia: Non-Small Cell Lung Cancer Market, by Type, 2020-2034 (USD Billion)
  - 8.5.8.2. Indonesia: Non-Small Cell Lung Cancer Market, by Treatment, 2020-2034 (USD Billion)
  - 8.5.8.3. Indonesia: Non-Small Cell Lung Cancer Market, by Distribution Channel, 2020-2034 (USD Billion)
- 8.5.9. Non-Small Cell Lung Cancer Market - South Korea
  - 8.5.9.1. South Korea: Non-Small Cell Lung Cancer Market, by Type, 2020-2034 (USD Billion)
  - 8.5.9.2. South Korea: Non-Small Cell Lung Cancer Market, by Treatment, 2020-2034 (USD Billion)
  - 8.5.9.3. South Korea: Non-Small Cell Lung Cancer Market, by Distribution Channel, 2020-2034 (USD Billion)
- 8.5.10. Non-Small Cell Lung Cancer Market - Australia
  - 8.5.10.1. Australia: Non-Small Cell Lung Cancer Market, by Type, 2020-2034 (USD Billion)
  - 8.5.10.2. Australia: Non-Small Cell Lung Cancer Market, by Treatment, 2020-2034 (USD Billion)
  - 8.5.10.3. Australia: Non-Small Cell Lung Cancer Market, by Distribution Channel, 2020-2034 (USD Billion)
- 8.5.11. Non-Small Cell Lung Cancer Market - Rest of Asia Pacific
  - 8.5.11.1. Rest of Asia Pacific: Non-Small Cell Lung Cancer Market, by Type, 2020-2034 (USD Billion)
  - 8.5.11.2. Rest of Asia Pacific: Non-Small Cell Lung Cancer Market, by Treatment, 2020-2034 (USD Billion)
  - 8.5.11.3. Rest of Asia Pacific: Non-Small Cell Lung Cancer Market, by Distribution Channel, 2020-2034 (USD Billion)
8.6. Non-Small Cell Lung Cancer Market - Middle East & Africa
- 8.6.1. Middle East & Africa: Non-Small Cell Lung Cancer Market, by Type, 2020-2034 (USD Billion)
- 8.6.2. Middle East & Africa: Non-Small Cell Lung Cancer Market, by Treatment, 2020-2034 (USD Billion)
- 8.6.3. Middle East & Africa: Non-Small Cell Lung Cancer Market, by Distribution Channel, 2020-2034 (USD Billion)
- 8.6.4. Non-Small Cell Lung Cancer Market - Saudi Arabia
  - 8.6.4.1. Saudi Arabia: Non-Small Cell Lung Cancer Market, by Type, 2020-2034 (USD Billion)
  - 8.6.4.2. Saudi Arabia: Non-Small Cell Lung Cancer Market, by Treatment, 2020-2034 (USD Billion)
  - 8.6.4.3. Saudi Arabia: Non-Small Cell Lung Cancer Market, by Distribution Channel, 2020-2034 (USD Billion)
- 8.6.5. Non-Small Cell Lung Cancer Market - UAE
  - 8.6.5.1. UAE: Non-Small Cell Lung Cancer Market, by Type, 2020-2034 (USD Billion)
  - 8.6.5.2. UAE: Non-Small Cell Lung Cancer Market, by Treatment, 2020-2034 (USD Billion)
  - 8.6.5.3. UAE: Non-Small Cell Lung Cancer Market, by Distribution Channel, 2020-2034 (USD Billion)
- 8.6.6. Non-Small Cell Lung Cancer Market - Israel
  - 8.6.6.1. Israel: Non-Small Cell Lung Cancer Market, by Type, 2020-2034 (USD Billion)
  - 8.6.6.2. Israel: Non-Small Cell Lung Cancer Market, by Treatment, 2020-2034 (USD Billion)
  - 8.6.6.3. Israel: Non-Small Cell Lung Cancer Market, by Distribution Channel, 2020-2034 (USD Billion)
- 8.6.7. Non-Small Cell Lung Cancer Market - South Africa
  - 8.6.7.1. South Africa: Non-Small Cell Lung Cancer Market, by Type, 2020-2034 (USD Billion)
  - 8.6.7.2. South Africa: Non-Small Cell Lung Cancer Market, by Treatment, 2020-2034 (USD Billion)
  - 8.6.7.3. South Africa: Non-Small Cell Lung Cancer Market, by Distribution Channel, 2020-2034 (USD Billion)
- 8.6.8. Non-Small Cell Lung Cancer Market - Rest of Middle East & Africa
  - 8.6.8.1. Rest of Middle East & Africa: Non-Small Cell Lung Cancer Market, by Type, 2020-2034 (USD Billion)
  - 8.6.8.2. Rest of Middle East & Africa: Non-Small Cell Lung Cancer Market, by Treatment, 2020-2034 (USD Billion)
  - 8.6.8.3. Rest of Middle East & Africa: Non-Small Cell Lung Cancer Market, by Distribution Channel, 2020-2034 (USD Billion)
8.7. Non-Small Cell Lung Cancer Market - Latin America
- 8.7.1. Latin America: Non-Small Cell Lung Cancer Market, by Type, 2020-2034 (USD Billion)
- 8.7.2. Latin America: Non-Small Cell Lung Cancer Market, by Treatment, 2020-2034 (USD Billion)
- 8.7.3. Latin America: Non-Small Cell Lung Cancer Market, by Distribution Channel, 2020-2034 (USD Billion)
- 8.7.4. Non-Small Cell Lung Cancer Market - Mexico
  - 8.7.4.1. Mexico: Non-Small Cell Lung Cancer Market, by Type, 2020-2034 (USD Billion)
  - 8.7.4.2. Mexico: Non-Small Cell Lung Cancer Market, by Treatment, 2020-2034 (USD Billion)
  - 8.7.4.3. Mexico: Non-Small Cell Lung Cancer Market, by Distribution Channel, 2020-2034 (USD Billion)
- 8.7.5. Non-Small Cell Lung Cancer Market - Brazil
  - 8.7.5.1. Brazil: Non-Small Cell Lung Cancer Market, by Type, 2020-2034 (USD Billion)
  - 8.7.5.2. Brazil: Non-Small Cell Lung Cancer Market, by Treatment, 2020-2034 (USD Billion)
  - 8.7.5.3. Brazil: Non-Small Cell Lung Cancer Market, by Distribution Channel, 2020-2034 (USD Billion)
- 8.7.6. Non-Small Cell Lung Cancer Market - Argentina
  - 8.7.6.1. Argentina: Non-Small Cell Lung Cancer Market, by Type, 2020-2034 (USD Billion)
  - 8.7.6.2. Argentina: Non-Small Cell Lung Cancer Market, by Treatment, 2020-2034 (USD Billion)
  - 8.7.6.3. Argentina: Non-Small Cell Lung Cancer Market, by Distribution Channel, 2020-2034 (USD Billion)
- 8.7.7. Non-Small Cell Lung Cancer Market - Rest of Latin America
  - 8.7.7.1. Rest of Latin America: Non-Small Cell Lung Cancer Market, by Type, 2020-2034 (USD Billion)
  - 8.7.7.2. Rest of Latin America: Non-Small Cell Lung Cancer Market, by Treatment, 2020-2034 (USD Billion)
  - 8.7.7.3. Rest of Latin America: Non-Small Cell Lung Cancer Market, by Distribution Channel, 2020-2034 (USD Billion)

9. Competitive Landscape

9.1. Expansion and Acquisition Analysis
- 9.1.1. Expansion
- 9.1.2. Acquisitions
9.2. Partnerships/Collaborations/Agreements/Exhibitions

10. Company Profiles

10.1. Amgen Inc.
- 10.1.1. Company Overview
- 10.1.2. Financial Performance
- 10.1.3. Product Benchmarking
- 10.1.4. Recent Development
10.2. AstraZeneca PLC
- 10.2.1. Company Overview
- 10.2.2. Financial Performance
- 10.2.3. Product Benchmarking
- 10.2.4. Recent Development
10.3. Beigene Ltd.
- 10.3.1. Company Overview
- 10.3.2. Financial Performance
- 10.3.3. Product Benchmarking
- 10.3.4. Recent Development
10.4. Bristol-Myers Squibb Company
- 10.4.1. Company Overview
- 10.4.2. Financial Performance
- 10.4.3. Product Benchmarking
- 10.4.4. Recent Development
10.5. Eli Lilly And Company
- 10.5.1. Company Overview
- 10.5.2. Financial Performance
- 10.5.3. Product Benchmarking
- 10.5.4. Recent Development
10.6. Exelixis Inc.
- 10.6.1. Company Overview
- 10.6.2. Financial Performance
- 10.6.3. Product Benchmarking
- 10.6.4. Recent Development
10.7. Johnson & Johnson
- 10.7.1. Company Overview
- 10.7.2. Financial Performance
- 10.7.3. Product Benchmarking
- 10.7.4. Recent Development
10.8. Merck & Co., Inc.
- 10.8.1. Company Overview
- 10.8.2. Financial Performance
- 10.8.3. Product Benchmarking
- 10.8.4. Recent Development
10.9. Mirati Therapeutics Inc.
- 10.9.1. Company Overview
- 10.9.2. Financial Performance
- 10.9.3. Product Benchmarking
- 10.9.4. Recent Development
10.10. Novartis AG
- 10.10.1. Company Overview
- 10.10.2. Financial Performance
- 10.10.3. Product Benchmarking
- 10.10.4. Recent Development
10.11. Pfizer Inc.
- 10.11.1. Company Overview
- 10.11.2. Financial Performance
- 10.11.3. Product Benchmarking
- 10.11.4. Recent Development
10.12. Roche Holding AG
- 10.12.1. Company Overview
- 10.12.2. Financial Performance
- 10.12.3. Product Benchmarking
- 10.12.4. Recent Development